Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) Shares Up 1.1% – Here’s What Happened

Invesco Biotechnology & Genome ETF (NYSEARCA:PBE)’s share price rose 1.1% during mid-day trading on Monday . The stock traded as high as $96.32 and last traded at $95.97. Approximately 15,776 shares changed hands during trading, an increase of 13% from the average daily volume of 13,907 shares. The stock had previously closed at $94.91.

Invesco Biotechnology & Genome ETF Stock Up 1.1%

The firm’s 50 day moving average is $93.80 and its 200-day moving average is $86.34. The firm has a market cap of $302.31 million, a PE ratio of 20.44 and a beta of 0.71.

Institutional Investors Weigh In On Invesco Biotechnology & Genome ETF

Several institutional investors and hedge funds have recently added to or reduced their stakes in PBE. Royal Bank of Canada increased its position in Invesco Biotechnology & Genome ETF by 25.9% during the 1st quarter. Royal Bank of Canada now owns 59,329 shares of the company’s stock worth $4,698,000 after purchasing an additional 12,215 shares in the last quarter. Cetera Investment Advisers lifted its position in Invesco Biotechnology & Genome ETF by 2.0% during the first quarter. Cetera Investment Advisers now owns 23,139 shares of the company’s stock valued at $1,832,000 after buying an additional 464 shares in the last quarter. Rockefeller Capital Management L.P. lifted its position in Invesco Biotechnology & Genome ETF by 6.7% during the fourth quarter. Rockefeller Capital Management L.P. now owns 10,666 shares of the company’s stock valued at $876,000 after buying an additional 666 shares in the last quarter. Archford Capital Strategies LLC grew its stake in Invesco Biotechnology & Genome ETF by 6.7% during the second quarter. Archford Capital Strategies LLC now owns 6,252 shares of the company’s stock worth $560,000 after buying an additional 395 shares during the period. Finally, Kestra Advisory Services LLC grew its stake in Invesco Biotechnology & Genome ETF by 7.0% during the first quarter. Kestra Advisory Services LLC now owns 6,280 shares of the company’s stock worth $497,000 after buying an additional 411 shares during the period.

Invesco Biotechnology & Genome ETF Company Profile

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies. The Fund will normally invest at least 90% of its total assets in common stocks that consists of the Index. The Index is designed to provide capital appreciation by evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.